<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39447830</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-5653</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Fertility and sterility</Title><ISOAbbreviation>Fertil Steril</ISOAbbreviation></Journal><ArticleTitle>Antibody-dependent complement-mediated sperm cytotoxicity in the endocervix is a dominant contraceptive mechanism of ZB-06 vaginal film.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0015-0282(24)02320-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fertnstert.2024.10.026</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nador</LastName><ForeName>Ellena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mausser</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marathe</LastName><ForeName>Jai G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Politch</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thurman</LastName><ForeName>Andrea R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Dare Bioscience, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whaley</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>ZabBio, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Deborah J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts. Electronic address: deborah.anderson@bmc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Fertil Steril</MedlineTA><NlmUniqueID>0372772</NlmUniqueID><ISSNLinking>0015-0282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of Interests E.N. reports funding from National Institutes of Health P50 HD096957 and R33 HD099745 for the submitted work. E.M. reports funding from National Institutes of Health P50 HD096957 and R33 HD099745 for the submitted work. J.G.M. reports funding from OT2 HL162087-01 RECOVER Cohort Phase II Adult Clinical Recovery Cohort RECOVER, a research initiative from the National Institutes of Health (NIH), seeks to understand, prevent, and treat post-acute sequelae of SARS-CoV-2, including Long COVID, outside the submitted work. J.A.P. reports funding from National Institutes of Health P50 HD096957 for the submitted work. A.R.T. reports funding from National Institutes of Health P50 HD096957 for the submitted work. K.J.W. reports funding from National Institutes of Health P50 HD096957 for the submitted work; funding from KBio/Zab Master Service Agreement and R33 HD099745; patent for KBio, Inc. Thermostable KBl5A (aka HCA/HC4 variant); and Mapp Biopharmaceutical, Inc. (CEO), and ServareGMP (Board Member) outside the submitted work; is an owner of ZabBio, a company focused on the commercialization of antibody-based products. D.J.A. has nothing to disclose. Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39447830</ArticleId><ArticleId IdType="doi">10.1016/j.fertnstert.2024.10.026</ArticleId><ArticleId IdType="pii">S0015-0282(24)02320-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>